《通过使用RosettaAntibodyDesign（RAbD）对抗体80R的特异性开关进行工程改造，设计出对多种SARS-CoV-2变体具有纳摩尔结合亲和力的抗体，从而产生针对新型SARS-CoV-2病毒的潜在通用治疗性抗体》勘误 [《Heliyon》9(4)（2023年4月）e15032]
Corrigendum to "Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus" [Heliyon 9(4) (April 2023) e15032].
作者信息
Hernandez Nancy E, Jankowski Wojciech, Frick Rahel, Kelow Simon P, Lubin Joseph H, Simhadri Vijaya, Adolf-Bryfogle Jared, Khare Sagar D, Dunbrack Roland L, Gray Jeffrey J, Sauna Zuben E
机构信息
Hemostasis Branch 1, Division of Hemostasis, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation and Research U.S. FDA, Silver Spring, MD, USA.
Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.
出版信息
Heliyon. 2023 Jul 6;9(8):e17901. doi: 10.1016/j.heliyon.2023.e17901. eCollection 2023 Aug.
Abstract
[This corrects the article DOI: 10.1016/j.heliyon.2023.e15032.].
摘要
[本文更正了文章的数字对象标识符：10.1016/j.heliyon.2023.e15032。]
相似文献
1
Corrigendum to "Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus" [Heliyon 9(4) (April 2023) e15032].《通过使用RosettaAntibodyDesign（RAbD）对抗体80R的特异性开关进行工程改造，设计出对多种SARS-CoV-2变体具有纳摩尔结合亲和力的抗体，从而产生针对新型SARS-CoV-2病毒的潜在通用治疗性抗体》勘误 [《Heliyon》9(4)（2023年4月）e15032]
Heliyon. 2023 Jul 6;9(8):e17901. doi: 10.1016/j.heliyon.2023.e17901. eCollection 2023 Aug.
2
Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus.通过使用Rosetta抗体设计（RAbD）工程改造抗体80R的特异性开关，针对多种SARS-CoV-2变体设计出具有纳摩尔结合力的抗体，从而为新型SARS-CoV-2病毒开发出具有潜在广泛适用性的治疗性抗体。
Heliyon. 2023 Apr;9(4):e15032. doi: 10.1016/j.heliyon.2023.e15032. Epub 2023 Apr 3.
3
RosettaAntibodyDesign (RAbD): A general framework for computational antibody design.罗塞塔抗体设计（RAbD）：一种通用的计算抗体设计框架。
PLoS Comput Biol. 2018 Apr 27;14(4):e1006112. doi: 10.1371/journal.pcbi.1006112. eCollection 2018 Apr.
4
Corrigendum to "Error rates in SARS-CoV-2 testing examined with Bayes' theorem" [Heliyon 7, (4), (April 2021), Article e06905].《用贝叶斯定理检验的SARS-CoV-2检测中的错误率》勘误[《Heliyon》7卷，（4）期，（2021年4月），文章编号e06905]
Heliyon. 2022 Feb;8(2):e08836. doi: 10.1016/j.heliyon.2022.e08836. Epub 2022 Jan 28.
5
Corrigendum to "PRAK-03202: A triple antigen virus-like particle vaccine candidate against SARS CoV-2"[Heliyon 7 (10) (October 2021) e08124].《“PRAK - 03202：一种针对SARS CoV - 2的三联抗原病毒样颗粒候选疫苗”的勘误》[《Heliyon》7(10)(2021年10月)e08124]
Heliyon. 2021 Oct;7(10):e08201. doi: 10.1016/j.heliyon.2021.e08201. Epub 2021 Oct 21.
6
Corrigendum to "Presymptomatic viral shedding and infective ability of SARS-CoV-2; a case report" [Heliyon 7, (2), (February 2021), Article e06328].《新型冠状病毒无症状病毒脱落与感染能力；一例报告》的勘误[《Heliyon》7卷，（2）期，（2021年2月），文章编号e06328]
Heliyon. 2022 Feb;8(2):e08906. doi: 10.1016/j.heliyon.2022.e08906. Epub 2022 Feb 5.
7
Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies.通过标志性 SARS-CoV-1 抗体的成熟实现对 SARS-CoV-2 的有效结合和中和。
MAbs. 2021 Jan-Dec;13(1):1922134. doi: 10.1080/19420862.2021.1922134.
8
Corrigendum to "Transmissibility of the variant of concern for SARS-CoV-2 in six regions" [Heliyon Volume 10, Issue 11, June 15, 2024, Article e32164].《关于新型冠状病毒肺炎关切变异株在六个地区的传播性》勘误 [《Heliyon》第10卷，第11期，2024年6月15日，文章e32164]
Heliyon. 2025 Feb 26;11(4):e42892. doi: 10.1016/j.heliyon.2025.e42892. eCollection 2025 Feb 28.
9
Corrigendum to "Cross-sectional analysis of students and school workers reveals a high number of asymptomatic SARS-CoV-2 infections during school reopening in Brazilian cities" [Heliyon 8 (11) (November 2022) Article e11368].《“学生和学校工作人员的横断面分析显示，巴西城市学校重新开学期间无症状SARS-CoV-2感染数量众多”的勘误》[《Heliyon》8(11)(2022年11月)文章e11368]
Heliyon. 2023 Mar;9(3):e14398. doi: 10.1016/j.heliyon.2023.e14398. Epub 2023 Mar 15.
10
Application of an integrated computational antibody engineering platform to design SARS-CoV-2 neutralizers.应用集成计算抗体工程平台设计新型冠状病毒2型中和抗体
Antib Ther. 2021 Jun 24;4(2):109-122. doi: 10.1093/abt/tbab011. eCollection 2021 Apr.
Zotero 插件